# Best Peptides for Liver Health, NAFLD & MASH: Evidence (2026)

> An evidence-first ranking of the peptide drugs studied for fatty liver disease (NAFLD/MASLD) and steatohepatitis (MASH) — anchored in biopsy-confirmed human RCTs, not marketing.

*Published 2026-07-01 · Updated 2026-07-01 · By Elena Soto, PharmD*

The short answer
Unusually for a "peptides for X" topic, fatty liver disease has real human proof. **Semaglutide is the only peptide with a Phase 3, biopsy-confirmed trial and the first FDA-approved for MASH** (August 2025). Tirzepatide and survodutide have strong Phase 2 biopsy data; retatrutide posts the biggest liver-fat drop but only on imaging; tesamorelin's only liver trial was HIV-only. Research peptides like BPC-157 have **no human liver-disease efficacy data**, and none of these agents reverses established cirrhosis.[1](https://peptidevox.com/#r1)[3](https://peptidevox.com/#r3)

Non-alcoholic fatty liver disease (NAFLD, now often called MASLD) and its progressive form, steatohepatitis (NASH/MASH), are serious metabolic conditions that can advance to fibrosis, cirrhosis and liver cancer. This is an **informational and editorial review of the published literature — not medical advice, not a protocol, and not a sourcing or buying guide.** The most effective agents discussed here are FDA-approved or investigational prescription peptide drugs with boxed warnings and meaningful side effects — they are not supplements, and doses are reported strictly as seen in the trials or FDA labeling. Several are prohibited in sport (WADA), and "research-chemical" or compounded sourcing carries real regulatory and safety risk.[22](https://peptidevox.com/#r22)[26](https://peptidevox.com/#r26)

## Why do peptide drugs help fatty liver at all?

NAFLD/MASLD is, at its core, a disease of substrate overload and metabolic dysfunction: excess hepatic fat driven by caloric surplus, insulin resistance, de novo lipogenesis and visceral adiposity, which in a subset progresses to inflammation, ballooning (MASH) and then fibrosis.[23](https://peptidevox.com/#r23) The peptides that work here are the same incretin and gut-hormone drugs transforming obesity and diabetes care, and they act on overlapping but distinct levers. **GLP-1 receptor agonism (semaglutide)** is the validated anchor: it drives substantial weight and visceral-fat loss, reduces caloric intake and improves insulin sensitivity, so the resulting drop in hepatic fat delivery lets steatohepatitis resolve. In ESSENCE the liver benefit paralleled a −10.5% body-weight reduction versus −2.0% on placebo, underscoring that the effect is largely — though not entirely — weight-mediated.[1](https://peptidevox.com/#r1)

**Adding GIP (tirzepatide)** amplifies weight loss and insulin sensitization, producing a clear dose-dependent histologic response.[6](https://peptidevox.com/#r6) **Adding glucagon (survodutide, retatrutide)** introduces a more liver-directed mechanism: glucagon-receptor agonism increases hepatic fatty-acid oxidation and reduces de novo lipogenesis through pathways partly independent of caloric restriction — the rationale for why dual and triple agonists may clear liver fat even more aggressively than pure GLP-1 drugs.[9](https://peptidevox.com/#r9)[13](https://peptidevox.com/#r13) **Tesamorelin** works through a narrower, double-edged growth-hormone lever: as a GHRH analog it raises pulsatile GH and IGF-1, reducing visceral fat and possibly suppressing hepatic de novo lipogenesis — but GH excess is diabetogenic, so this lever cuts the wrong way for the insulin resistance underlying most fatty liver.[15](https://peptidevox.com/#r15)

## Which peptide has the strongest evidence for MASH in 2026?

Semaglutide, without qualification. It is the only peptide with a Phase 3 biopsy-confirmed RCT and the only one FDA-approved for the condition. In the Phase 3 [ESSENCE trial (NCT04822181)](https://www.nejm.org/doi/full/10.1056/NEJMoa2413258), published in the *New England Journal of Medicine*, once-weekly semaglutide 2.4 mg resolved steatohepatitis without worsening fibrosis in 62.9% of patients versus 34.3% on placebo, and improved fibrosis in 36.8% versus 22.4%, at 72 weeks.[1](https://peptidevox.com/#r1) On August 15, 2025 the FDA approved Wegovy for adults with noncirrhotic MASH and moderate-to-advanced (F2–F3) fibrosis — the second-ever MASH drug after resmetirom and the first GLP-1 indicated for liver disease.[3](https://peptidevox.com/#r3)[4](https://peptidevox.com/#r4)

Close behind on data quality is tirzepatide, whose Phase 2 **SYNERGY-NASH** trial (n=190) showed dose-dependent MASH resolution in 51.8% / 62.8% / 73.3% of patients (5/10/15 mg) versus 13.2% on placebo at 52 weeks — figures that numerically rival or exceed semaglutide.[6](https://peptidevox.com/#r6) But it is Phase 2, not Phase 3, and carries no FDA MASH indication yet.[8](https://peptidevox.com/#r8) Survodutide, a glucagon/GLP-1 dual agonist, met its biopsy-confirmed Phase 2 primary endpoint (MASH improvement in up to 62% versus 14% placebo) and holds FDA Breakthrough Therapy and Fast Track designations, with Phase 3 LIVERAGE underway — but remains investigational.[9](https://peptidevox.com/#r9)[10](https://peptidevox.com/#r10)

  Peptides for fatty liver — evidence at a glance (2026)

    PeptideBest evidenceRegulatory statusGrade

    Semaglutide (GLP-1)Phase 3 biopsy RCT (ESSENCE): 62.9% vs 34.3% MASH resolutionFDA-approved for MASH (Aug 2025)A
    Tirzepatide (GIP/GLP-1)Phase 2 biopsy RCT (SYNERGY-NASH): up to 73.3% resolutionApproved for T2D/obesity; off-label for MASHA
    Survodutide (glucagon/GLP-1)Phase 2 biopsy RCT: up to 62% vs 14% MASH improvementInvestigational; Breakthrough/Fast TrackB
    Retatrutide (triple agonist)Phase 2a imaging (MRI-PDFF): up to ~86% liver-fat dropInvestigational; no biopsy dataB
    Tesamorelin (GHRH analog)RCT (n=61) — HIV-only: ~37% relative liver-fat reductionApproved for HIV lipodystrophy; off-label for NAFLDB

## Doesn't retatrutide's ~86% liver-fat drop make it the best?

Retatrutide, a triple GIP/GLP-1/glucagon agonist, produced the largest liver-fat reduction of any agent here — but the endpoint is the whole story. In a Phase 2a MASLD sub-study (n=98) it cut liver fat by up to ~86% by MRI-PDFF, with roughly 85–90% of participants achieving steatosis resolution (under 5% liver fat) at the top doses, and falls in the cell-death marker K-18 and the fibrogenesis marker pro-C3.[13](https://peptidevox.com/#r13)[14](https://peptidevox.com/#r14) Those are spectacular numbers — but they come from **imaging, not liver biopsy**, in a small sub-study, so retatrutide has no histologic MASH-resolution or fibrosis data. Liver-fat reduction is a necessary but not sufficient surrogate; clearing fat on a scan is not the same as resolving steatohepatitis or improving fibrosis on tissue. That is exactly what its Phase 3 program, with histology, is built to test — which is why we grade it B, not A, despite the biggest headline.[13](https://peptidevox.com/#r13)

Endpoint literacy matters
Biopsy-confirmed MASH resolution and fibrosis improvement are the real endpoints. MRI-PDFF liver-fat percentage is a surrogate. A drug can post a huge liver-fat number and still be unproven for the outcomes patients care about — retatrutide is the clearest example.[13](https://peptidevox.com/#r13)

## What does the evidence NOT support?

Several popular claims outrun the data. **BPC-157 for "liver detox"** is a marketing story, not a clinical one: its hepatoprotective evidence is entirely preclinical — rat models of carbon-tetrachloride toxicity, bile-duct ligation, alcohol and ischemia-reperfusion — with no completed human trials for any indication, let alone NAFLD/MASH.[24](https://peptidevox.com/#r24)[25](https://peptidevox.com/#r25) The same holds for TB-500 (thymosin-β4) and MOTS-c: no qualifying human efficacy trials for fatty liver exist; their claims rest on mechanism or animal data (Grade C/D) and should not be presented as liver therapies. **Tesamorelin as a general-population NAFLD treatment** is likewise unsupported: its only liver RCT was HIV-specific (n=61), there are no published non-HIV efficacy results, and the general-population program has stalled seeking a partner.[19](https://peptidevox.com/#r19)

Finally, **none of these drugs reverses cirrhosis.** The semaglutide approval and the survodutide and tirzepatide trials are explicitly for noncirrhotic MASH (F2–F3); efficacy in compensated cirrhosis is still under investigation (for example the dedicated LIVERAGE-Cirrhosis study) and not established.[3](https://peptidevox.com/#r3)[11](https://peptidevox.com/#r11) And a 2026 regulatory note: the FDA has resolved the semaglutide and tirzepatide shortages and, as of April 30, 2026, proposed permanently barring 503B outsourcing facilities from compounding these molecules from bulk substances — routine compounding is not authorized, and gray-market vials carry dosing-error and contamination risk.[26](https://peptidevox.com/#r26)[27](https://peptidevox.com/#r27)

## How should readers weigh these options?

Rank by the strength of human evidence for liver disease specifically. Semaglutide is the reference standard — Phase 3 biopsy proof plus an FDA MASH indication. Tirzepatide is close on data quality but not yet approved for MASH. Survodutide and retatrutide are investigational: survodutide has biopsy endpoints and Breakthrough status, retatrutide has the biggest imaging numbers but no histology. Tesamorelin is a real but narrow HIV-only RCT with a mechanism that cuts against most fatty liver.[1](https://peptidevox.com/#r1)[15](https://peptidevox.com/#r15)

**Bottom line.** For fatty liver, the strongest peptides are not obscure research compounds — they are the incretin and gut-hormone drugs, and they work in large double-blind histology trials, with semaglutide now carrying an FDA MASH indication. From a root-cause perspective this matters: every one of these agents acts substantially through weight and visceral-fat loss — powerful levers layered on top of the diet, alcohol, fructose and metabolic drivers that cause fatty liver in the first place, and their benefit tracks (and largely reverses with) those upstream changes. None reverses established cirrhosis. Regulatory facts here are current as of June 2026 and should be re-verified for later developments; fatty liver disease must be diagnosed and managed by a qualified physician.

---
Source: https://peptidevox.com/weight-and-metabolic/peptides-for-liver-health-nafld
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt